Resources

2026 ∙ JCVI

Flu vaccination programme 2026 to 2027: briefing for primary schools

2026

Hexavalent Switch Evidence-to-Recommendation Framework

2026 ∙ Gerald Etapelong Sume, Wedyan Meshreky, Md Sharifuzzaman, Messeret Shibeshi, Quamrul Hasan

Concordance of self-assessment and self-reporting of National Immunization Technical Advisory Group process indicators in the Eastern Mediterranean Region

2026 ∙ Ministério da Saúde

Vaccination Strategy in Schools - 2026

2026 ∙ Matthew Tunis, Robyn Harrison, Kaeli Ramotar, Ashleigh Tuite, Christina Jensen, Krista Wilkinson, Kelsey Young, Joseline Zafack, Marina Salvadori, Adrienne Stevens, Dubey, V., Erin Henry

Canada’s National Advisory Committee on Immunization (NACI) in 2025: Celebrating 60 years of service, a decade of change, and a dynamic future ahead

2026 ∙ STIKO

Recommendations by the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute – 2026

2026 ∙ Public Health Agency of Canada

Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease: use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine

2026 ∙ Public Health Agency of Canada

Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease

2026 ∙ Public Health Agency of Canada

Updated guidance on the assessment of exposure to a potentially rabid animal

2026 ∙ Superior Health Council

5192 results found

Flu vaccination programme 2026 to 2027: briefing for primary schools

Hexavalent Switch Evidence-to-Recommendation Framework

Concordance of self-assessment and self-reporting of National Immunization Technical Advisory Group process indicators in the Eastern Mediterranean Region

Vaccination Strategy in Schools - 2026

Canada’s National Advisory Committee on Immunization (NACI) in 2025: Celebrating 60 years of service, a decade of change, and a dynamic future ahead

Recommendations by the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute – 2026

Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease: use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine

Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease

Updated guidance on the assessment of exposure to a potentially rabid animal

Belgian mpox vaccination strategy (revision 2026)